RTP Mobile Logo
Oncology Nursing Update, Melanoma Edition, Issue 1, 2016
Released February 2016

Featuring interviews with Dr Evan J Lipson and Ms Stephanie Andrews. (Audio Content)

CE Disclosures and Faculty Information

    Skin cancer is the most commonly diagnosed cancer in the United States. Melanoma accounts for less than 2% of all skin cancer cases but the vast majority of skin cancer deaths. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes for patients with melanoma. However, the advent of targeted therapy and immunotherapy has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with melanoma, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses with expertise in the field. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with melanoma.

    To present the most current research developments and to provide the perspectives of nurse practitioners and clinical investigators on the diagnosis and treatment of melanoma.


    • Recall the scientific rationale for the ongoing investigation of immunotherapeutic approaches in melanoma.
    • Recognize immune-related adverse events associated with ipilimumab and nivolumab alone and in combination, and offer supportive management strategies to minimize and/or manage these side effects.
    • Evaluate existing and emerging research information demonstrating the benefit of combining BRAF and MEK inhibitors for patients with BRAF mutation-positive metastatic melanoma, and use this information to guide treatment planning for these patients.
    • Counsel patients regarding the risk of adverse events associated with BRAF and MEK inhibitor therapy, and implement appropriate surveillance and management strategies.


    CNE credit is no longer available for this issue


    CNE credit is no longer available for this issue

    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    CNE credit is no longer available for this issue

    This is an audio CNE program.

    CNE credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Ms Andrews has no relevant conflicts of interest to disclose. The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LipsonAdvisory Committee: Amgen Inc, Castle Biosciences Incorporated; Consulting Agreements: Bristol-Myers Squibb Company, Merck.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: February 2016
    Expiration date: February 2017

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Oncology Nursing Update, Melanoma Edition, Issue 1, 2016
Released February 2016

Featuring interviews with Dr Evan J Lipson and Ms Stephanie Andrews. (Audio Content)

Read print: